One of CGI’s Most Powerful Tools in Our Immuno-Oncology Portfolio: Multiplex Gene Expression Across 770 Genes

Written by: Anna Israyelyan, MD, PhD
Manager, Biopharma Solutions

Published on:
November 21st, 2017

Anna Israyelyan, MD, PhD
Dr. Israyelyan joined CGI in 2015. She has over 15 years of extensive cancer research and management experience in industry and academia covering wide range of medical areas, including basic, translational, and clinical research. Anna is an active member of the American Society of Hematology (ASH), the American Association for Cancer Research (AACR), and American Association for the Advancement of Science (AAAS). Dr. Israyelyan has a scientific advisory role with matrix management of scientific, technical, and operational aspects related to various biopharma projects and collaborations involving biomarkers in solid tumors and hematologic malignancies.

At CGI, we adopt a technology- and platform-agnostic approach to our biopharma service portfolio. It enables us to offer a wide range of fit-for-purpose services, specifically-tailored to our clients’ overall scientific and clinical objectives. Continually adding to our comprehensive menu of clinically-validated diagnostic tests, and making strategic investments into cutting-edge technologies are keys to our success as service provider. A perfect example of targeted, scientifically-aligned addition to our solutions suite is the nanoString nCounter® technology platform.  It’s become a prominent component of many of our immuno-oncology (IO) trials.

nanoString nCounter® is a unique system with a proven technology for the rapid translation of genomic discovery to a clinically validated assay. Utilizing the nCounter® barcoding technology and the power of 3D Biology Technology, we can compare genotype and gene and protein expression for up to 800 targets in a single view – a single reaction with no amplification, for multiplexed, single-molecule digital counting of DNAs, RNAs, and proteins.

We offer all of nanoString’s panels on the company’s menu and have a collaborative relationship with the company to integrate custom content and panel designs for our clients.   nanoString’s platform provides a simple and fast workflow with minimal hands-on time, streamlined analysis, and proven and robust performance – even when using challenging samples. The technology is compatible with a wide range of different sample types, including formalin-fixed paraffin-embedded (FFPE) tissues, cell lysates, urine, etc.

Accelerating your IO program with the PanCancer Immune Profiling Panel

The nCounter® PanCancer Immune Profiling panel is one of nanoString’s most popular panels in the biopharma community. It is part of various IO programs studying the biomarkers associated with therapeutic response to IO agents.

The PanCancer Immune Profiling panel is a multiplexed gene expression panel offering a novel set of 770 gene targets that combines markers for 24 different immune cell types and populations, various common cancer antigens covering all categories of immune response including key checkpoint blockade genes. The panel can be applied for the comprehensive profiling of the immune response in any cancer type and is optimized for IO research.

Here are some of the important applications and features of this novel panel:

  • Comprehensive profiling of the immune response optimized for IO research
  • Explore tumor-infiltrating lymphocytes (TILs) for the tumor microenvironment
  • Understand immune pathway activity (for single or combination studies)
  • Ability to customize with up to 30 additional genes
  • 3D-enabled for multi-analyte analysis of RNA, DNA, and protein

At CGI we are constantly innovating around new and existing technologies to further biomarker driven clinical trials and personalized medicine. nanoString panels are the latest addition to our comprehensive offerings and our burgeoning IO portfolio. We are always ready to help discover and enhance the great potential of precision therapeutics, including the IO drugs developed based on the proper characterization of the complex interplay between the tumor, microenvironment and immune response in cancer.

To learn more about this novel offering, please send me a note. I’d be happy to schedule time to help evaluate and discuss how PanCancer Immune Profiling panel, others based on the nCounter® system, as well as the rest on the CGI menu could be used to meet your clinical trial and drug development needs.

Comments

comments